Hot Features
Registrieren Sie sich, um in unseren aktiven Foren mit gleichgesinnten Anlegern zu diskutieren.
MiNK Therapeutics Inc is a clinical-stage biopharmaceutical company focused on developing allogeneic invariant natural killer T cell therapies to treat cancer and other life-threatening illnesses. MiNK Therapeutics Inc is a clinical-stage biopharmaceutical company focused on developing allogeneic invariant natural killer T cell therapies to treat cancer and other life-threatening illnesses.
NEW YORK, Dec. 18, 2024 (GLOBE NEWSWIRE) -- MiNK Therapeutics, Inc. (NASDAQ: INKT), a clinical-stage biopharmaceutical company pioneering the discovery, development, and commercialization of...
NEW YORK, Nov. 14, 2024 (GLOBE NEWSWIRE) -- MiNK Therapeutics, Inc. (NASDAQ: INKT), a clinical-stage biopharmaceutical company pioneering the discovery, development, and commercialization of...
NEW YORK, Nov. 11, 2024 (GLOBE NEWSWIRE) -- MiNK Therapeutics, Inc. (NASDAQ: INKT), a clinical-stage biopharmaceutical company pioneering the discovery, development, and commercialization of...
| Zeitraum † | Änderung | Änderung % | Handelsbeginn | Hoch | Niedrig | Durchsch. Volumen | VWAP | |
|---|---|---|---|---|---|---|---|---|
| 1 | 0.4698 | 88.641509434 | 0.53 | 1.0399 | 0.5005 | 143369 | 0.63157609 | CS |
| 4 | 0.2798 | 38.8611111111 | 0.72 | 1.0399 | 0.4632 | 88832 | 0.59173191 | CS |
| 12 | 0.3218 | 47.4631268437 | 0.678 | 1.0399 | 0.4632 | 48683 | 0.64698708 | CS |
| 26 | 0.06 | 6.384337093 | 0.9398 | 1.24 | 0.4632 | 53223 | 0.77292943 | CS |
| 52 | -0.0602 | -5.67924528302 | 1.06 | 1.9 | 0.4632 | 86530 | 0.96733328 | CS |
| 156 | -3.4702 | -77.6331096197 | 4.47 | 4.94 | 0.4632 | 107007 | 2.11087249 | CS |
| 260 | -11.0402 | -91.696013289 | 12.04 | 22.155 | 0.4632 | 107184 | 2.70339174 | CS |
Support: +44 (0) 203 8794 460 | support@advfn.de
Durch das Benutzen des ADVFN Angebotes akzeptieren Sie folgende Allgemeine Geschäftsbedingungen
Premium
